Available Clinical Trials

The Nevada Cancer Institute offers many diverse options for the treatment of cancer. For more detailed description of each trial, click on the type of cancer to open a PDF document with the details, including criteria for enrollment, for selected study.

» Phase I
» Genitourinary
» Lung

» Gastrointestinal
» Hematology
» Skin/Melanoma

» Phase IV

» Return to Clinical Trials main

Phase 1

Metastatic Solid Tumors	Phase I	Sandy (702)822-5174	A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients with Metastatic Solid Tumors
Advanced Solid Malignancies	Phase I/II	Dianna (702)822-5483	A Phase I/II, multi-center, open label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patient with advanced solid malignancies including patients with advanced breast cancer
Advanced Solid Malignancies	Phase I	Sandy (702)822-5174	A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer
Refractory or Metastatic Tumors	Phase I	Sandy (702)822-5174	A Phase I Study of EC0225 Administered Weeks 1 & 2 of a 4 Week Cycle
Advanced Solid Tumors	Phase I	Jennifer (702)822-5356	An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 with AMG 706, AMG 386 with Bevacizumab, AMG 386 with Sorafenib, and AMG 386 with Sunitinib in Adult Patients with Advanced Solid Tumors
Advanced Solid Malignancies	Phase I/II	Dianna (702)822-5483	A phase I/II, multi-center, open-label study of BGT226, administered orally in adult patients with advanced solid malignancies including patients with advanced breast cancer
Adult Cancer Patients	Phase I	Karen (702)822-5367	A Phase 1, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Advanced Solid Tumors & Malignant Pleural Mesothelioma	Phase II	Dianna (702)822-5483	Phase I/II study of a triplet combination of CBP501, pemetrexed and cisplatin in patients with advanced solid tumors and in chemotherapy-naïve patients with malignant pleural mesothelioma
Metastatic Cancer	Phase I	Annette (702)822-5177	Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-deoxycitidine (Decitabine) x 10 Days (M-F) with Escalating Doses of SC Pegylated (PEG) Interferon-alfa 2B: A Phase I Study with Molecular Correlates
Refractory or Relapsed Cancer	Phase I	Annette (702)822-5177	Phase 1 Study of MPC-3100 in Patients with Refractory or Relapsed Cancer

top ^

Gastrointestinal

top ^

Genitourinary

Prostate Cancer	Phase III	Carol (702)822-5449	A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Prostate Cancer	Phase III	Carol (702)822-5449	A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer	Phase III	Carol (702)822-5449	A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT by Chemotherapy With Docetaxel and Prednisone For Localized, High-Risk Prostate Cancer
Prostate Cancer	Phase Ib	Cheryl (702)822-5237	An open label, single arm, Phase Ib dose finding study of i.v. panobinostat (LBH589) with docetaxel & prednisone in patients with hormone refractory prostate cancer
Detection of Clear Cell Renal Cell Carcinoma	Phase III	Jacky (702)822-5393	A Comparative Study of PET/CT vs. Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients with Renal Masses Using Iodine-124 labeled Chimeric G250 (124IcG250)
Prostate Cancer	Phase I/II	Cheryl (702)822-5237	A Phase I/II open-label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MCS110 in patients with prostate cancer and bone metastases
Prostate Cancer	Phase III	Jacky (702)822-5393	A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Clear Cell Renal Cell Carcinoma	Phase I	Jennifer (702)822-5356	A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1411 Administered Every 14 Days in Subjects with Advanced or Recurrent Clear Cell Renal Cell Carcinoma
Metastatic Renal Cell Cancer	Phase III	Annette (702)822-5177	Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: Axis Trial
Metastatic Clear Cell Carcinoma of the Kidney	Phase II	Annette (702)822-5177	A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney
Non-Metastatic Hormone-Resistant Prostate Cancer	Phase III	Jacky (702)822-5393	A Phase III, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients.
Renal Cell Carcinoma	Phase III	Annette (702)822-5177	Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma.

top ^

Hematology

Multiple Myeloma	Phase Ib	Karen (702)822-5367	A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma
Chronic Lymphocytic Leukemia	Phase I/II	Karen (702)822-5367	A Phase1/2 Study of TRU-016 in Patients with Previously Treated Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma	Phase III	Karen (702)822-5367	A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab chemotherapy
Low Grade Recurrent B and T Cell Lymphoma	Phase I	Karen (702)822-5367	A Phase I Study of Intratumoral Poly-ICLC plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

top ^

Lung

Non-Small Cell Lung Cancer	Phase I/II	Christine (702)822-5456	Phase I/II Study of Pemetrexed (Alimta) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy followed by Every 21-day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage III A/B Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer	Phase III	Therica (702)822-5293	A randomized phase III comparison of standard-dose (60 Gy) versus high dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel in patients with stage IIIA/IIIB Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer	Phase II	Christine (702) 822-5456	Phase II study of a triplet combination of CBP501, pemetrexed and cisplatin as first line treatment in patients with locally advanced (stage IIIB with malignant pleural effusion or pericardial effusion) or metastatic (stage IV) non-squamous non small cell lung cancer (NSCLC)

top ^

Skin/Melanoma

Melanoma	Phase II	Annette (702)822-5177	A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma
Melanoma	Phase III	Annette (702)822-5177	Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC Melanoma Group

top ^